We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology
News

Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology

Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology
News

Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mirus Bio Enters into Agreement with Pfizer to Evaluate RNAi Delivery Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mirus Bio Corporation has announced it has entered into a two year, multimillion dollar agreement with Pfizer, Inc. to investigate and optimize gene silencing methods in animal models. The studies will utilize Mirus Bio's nucleic acid delivery platforms to target and suppress the expression of genes of interest to Pfizer.

"The lack of effective delivery methods has been the Achilles' heel impeding progress in the emerging field of RNA interference," commented Russell Smestad, Mirus Bio's President.

"We are excited that this agreement will enable us to accelerate the development of our platform technologies. This agreement further enhances our position as one of the industry leaders in providing enabling nucleic acid delivery solutions."

Mirus Bio has two distinct delivery platforms. The first is hydrodynamic intravascular injection, a method designed to deliver nucleic acids through the bloodstream to surrounding cells and tissues.

The second delivery platform involves formulating small interfering RNA (siRNA) into nanoparticles. Unlike the hydrodynamic platform, these nanoparticles are delivered systemically via standard intravenous injection.

Advertisement